ADPTAdaptive Biotechnologies Corp

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Chad Robins

Location

Washington, USA

Exchange

Nasdaq

Website

https://adaptivebiotech.com

Summary

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases.

Company Info

CEO

Chad Robins

Location

Washington, USA

Exchange

Nasdaq

Website

https://adaptivebiotech.com

Summary

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases.

AI Insights for ADPT
4 min read

Quick Summary

Adaptive Biotechnologies Corporation is a United States-based immune medicine company focused on reading and interpreting the adaptive immune system. The company develops platforms that sequence immune receptors, especially T-cell and B-cell receptors, to support disease monitoring, diagnostics, research, and drug discovery. Its main commercial clinical product is clonoSEQ, an FDA-cleared minimal residual disease test used primarily in blood cancers. It also offers immunoSEQ, a research-focused immunosequencing platform used by biopharma companies, academic researchers, and translational medicine teams. Its main customers include oncologists, clinical laboratories, hospitals, pharmaceutical companies, biotechnology companies, and researchers studying immune-mediated disease.

Strengths

•

Adaptive Biotechnologies has a differentiated technology platform built around immune-repertoire sequencing. clonoSEQ is FDA-cleared and has meaningful commercial traction in blood cancer MRD testing.

•

The company benefits from a growing base of tested patients, expanding reimbursement support, and integration into oncology workflows.

•

Its large immune-receptor dataset may become a strategic asset for diagnostics, drug discovery, and partnerships.

•

The company also has strong gross profit relative to revenue, suggesting that scale could improve margins if operating expenses are controlled.

Key Risks

•

A key risk is that reimbursement levels or payer coverage could change unfavorably and reduce revenue per test.

•

Another risk is that competitors develop alternative MRD or liquid biopsy tests that are cheaper, faster, or more broadly adopted.

•

Adaptive also faces execution risk because it must grow revenue while controlling operating expenses and moving toward sustainable free cash flow.

•

Regulatory, clinical validation, and guideline-adoption hurdles could slow expansion into new indications or uses.

What to Watch

The most recent quarter appears to have been shaped by continued clonoSEQ commercialization and improving visibility around reimbursement.
Adaptive announced that Medicare’s 2025 CLFS reimbursement rate for clonoSEQ MRD was set at $2,007, with MolDX episode pricing updated to $8,029.
This reimbursement development supports broader payer discussions and may strengthen access for covered blood cancer indications.
The company also announced a multi-year exclusive partnership with NeoGenomics to integrate clonoSEQ with COMPASS and CHART blood cancer assessment services.
In addition, company commentary highlighted that clonoSEQ MRD has become a business of more than $200 million, with more than 100,000 patients tested and strong clinical-revenue compound growth since 2021.

Price Drivers

•

ADPT’s stock price is likely driven by revenue growth in clonoSEQ, reimbursement developments, operating leverage, and investor confidence in the path to companywide profitability.

•

The company’s provided fundamentals show strong revenue relative to prior-stage biotech diagnostics businesses, but valuation remains demanding with an EV-to-revenue ratio above 15 and a price-to-book value near 28.

•

The stock also carries high beta above 2, so it may move sharply with changes in risk appetite, biotech sentiment, interest rates, and small-cap growth rotations.

•

News about Medicare reimbursement, payer agreements, clinical adoption, partnerships, or EBITDA progress can support the share price.

•

Conversely, any slowdown in procedure growth, reimbursement pressure, dilution risk, or evidence of slower commercialization could pressure the stock.

Recent News

•

Recent news has been generally focused on clonoSEQ growth, reimbursement, and partnerships.

•

Adaptive said clonoSEQ MRD is now a business generating more than $200 million, with more than 100,000 patients tested.

•

The company also reported that MRD growth has been supported by blood testing, community use, and EMR integration in an addressable market estimated around $5.5 billion.

•

Medicare’s finalized reimbursement rate and MolDX episode pricing update were important positive developments for access and payer negotiations.

•

Adaptive also entered a multi-year exclusive partnership with NeoGenomics to integrate clonoSEQ into COMPASS and CHART blood cancer assessment services.

Market Trends

•

Adaptive operates within several favorable healthcare and biotechnology trends.

•

Oncology care is increasingly moving toward precision diagnostics, measurable residual disease monitoring, and personalized treatment decisions.

•

Liquid biopsy and blood-based testing are gaining adoption because they can be less invasive and easier to repeat over time.

•

Payers are increasingly demanding clinical utility and cost-effectiveness evidence, which makes reimbursement both an opportunity and a challenge.

•

Broader biotech market conditions, interest rates, small-cap sentiment, and healthcare funding trends will also influence investor appetite for ADPT shares.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ADPT

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show